# Semaglutide Domain - DDD Project Instructions

This domain applies Domain-Driven Design (DDD) to semaglutide therapy systems, encompassing patient eligibility and enrollment, dosing and titration management, clinical outcomes monitoring, adverse event tracking, pharmacy and supply chain operations, and regulatory compliance and reporting.

## Bounded Contexts

1. Patient Eligibility and Enrollment Context - BMI assessment, comorbidity evaluation, insurance prior authorization, contraindication screening, informed consent, and treatment candidacy determination.
2. Dosing and Titration Context - dose escalation schedules, injection administration tracking, titration protocols, dose adjustment rules, missed dose management, and formulation selection (subcutaneous vs. oral).
3. Clinical Outcomes Monitoring Context - weight loss tracking, HbA1c measurement, cardiovascular risk factor monitoring, patient-reported outcomes, and efficacy benchmarking against clinical trial data.
4. Adverse Event Management Context - gastrointestinal side effect reporting, pancreatitis risk monitoring, thyroid monitoring, gallbladder event tracking, severity grading, and pharmacovigilance reporting.
5. Pharmacy and Supply Context - prescription processing, prior authorization workflows, specialty pharmacy coordination, cold chain management, inventory control, and patient assistance programs.
6. Regulatory and Compliance Context - FDA label adherence, off-label use documentation, REMS program requirements, clinical trial data referencing, and post-market surveillance reporting.

## Domain Principles

- Model the dosing lifecycle as a state machine with explicit transitions governed by titration protocols and clinical response.
- Represent patient eligibility as a composite value object that aggregates BMI, diagnosis codes, and contraindication checks.
- Capture the distinction between FDA-approved indications (type 2 diabetes, chronic weight management) as separate treatment pathways within the model.
- Enforce titration schedules and dose escalation rules as domain invariants that prevent unsafe prescribing patterns.
- Track adverse events with severity-graded domain events that trigger appropriate clinical and regulatory workflows.

## Topics

- strategic-design
- bounded-contexts
- context-map
- ubiquitous-language
- subdomains
- anti-corruption-layer
- aggregates
- entities
- value-objects
- domain-events
- repositories
- domain-services
- patient-eligibility-enrollment-context
- dosing-titration-context
- clinical-outcomes-monitoring-context
- adverse-event-management-context
- pharmacy-supply-context
- regulatory-compliance-context
- event-driven-architecture
- integration-patterns
- semaglutide-standards
- pharmacovigilance

## References

- Evans, E. (2003). Domain-Driven Design: Tackling Complexity in the Heart of Software. Addison-Wesley.
- Vernon, V. (2013). Implementing Domain-Driven Design. Addison-Wesley.
- Khononov, V. (2021). Learning Domain-Driven Design. O'Reilly Media.
- Wilding, J. P. H. et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.
- Marso, S. P. et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.
